Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Pro Medicus Limited ( (AU:PME) ) is now available.
Pro Medicus Limited reported a significant increase in its financial performance for the year ending June 30, 2025. The company achieved a 31.9% rise in revenue from customer contracts, reaching A$212.98 million, and a 39.2% increase in net profit attributable to members, totaling A$115.217 million. This growth reflects the company’s strong market positioning and operational efficiency, with a notable increase in dividends, highlighting its commitment to returning value to shareholders.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software and services. The company focuses on delivering innovative solutions for medical imaging, catering primarily to hospitals and diagnostic imaging centers.
Average Trading Volume: 172,667
Technical Sentiment Signal: Buy
Current Market Cap: A$31.67B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.